News Sentiment

TNXP sentiment intelligence

Tonix Pharmaceuticals Holding Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 12.43 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

81/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-0.8% over one week, +3.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Total debt per share of Tonix Pharmaceuticals Holding Corp. – GETTEX:TPM0

Market Reaction

Balanced read

57/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 81/100 classification
One-week reaction -0.8% Price digesting
Trend fit Trend inactive 3.5% over four weeks
Fair value -97.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 29
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 15
Market source 9
simplywall.st 4
TradingView 3
MT Newswires 3
GlobeNewswire 3
Quartr 2
Stock Traders Daily 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 9
Balance sheet 5
Guidance 2
Deals and strategy 2
Analyst action 2
Capital return 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
TradingView Direct company coverage

Total debt per share of Tonix Pharmaceuticals Holding Corp. – GETTEX:TPM0

The article focuses on the "Total debt per share" of Tonix Pharmaceuticals Holding Corp. (GETTEX:TPM0) as listed on TradingView. It appears to be a financial data page rather than a detailed news article. The content provides navigational links and information about TradingView's

Tone
Neutral 50/100
Event
Balance sheet
Published
21 Jul 2026 04:10
Source
TradingView
Quartr Direct company coverage

Tonix Pharmaceuticals (TNXP) Investor presentation Summary

Tonix Pharmaceuticals has launched Tonmya, a sublingual tablet for fibromyalgia, which has achieved $5.1 million in net sales and secured broad commercial and government insurance coverage. The company has a strong cash position of $185.5 million and an extensive pipeline of drug

Tone
Positive 73/100
Event
Balance sheet
Published
18 Jul 2026 01:11
Source
Quartr
Market source Direct company coverage

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

Tonix Pharmaceuticals announced the publication of a study in the Journal of Virology that assesses the virulence of the 2022 mpox outbreak strain (clade IIb) compared to the 2003 strain (clade IIa) using new murine models. The research found that the clade IIb strain is 100 to 1

Tone
Positive 73/100
Event
Market update
Published
16 Jul 2026 01:11
Source
Market source
Stock Titan Direct company coverage

Tonix Paper Introduces Three New Mouse Models for Mpox Vaccine Research

Tonix Pharmaceuticals announced that the Journal of Virology published its research on new mpox animal models, revealing that the 2022 clade IIb strain is 100 to 100,000-fold less virulent than the 2003 clade IIa strain. The study expands existing mouse models and introduces thre

Tone
Positive 72/100
Event
Market update
Published
15 Jul 2026 12:46
Source
Stock Titan
Stock Traders Daily Direct company coverage

Precision Trading with Tonix Pharmaceuticals Holding Corp. (TNXP) Risk Zones

This article analyzes Tonix Pharmaceuticals Holding Corp. (TNXP), highlighting a mid-channel oscillation pattern and a weak long-term outlook despite positive sentiment. It details distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specifi

Tone
Negative 29/100
Event
Guidance
Published
14 Jul 2026 23:46
Source
Stock Traders Daily
Quiver Quantitative Direct company coverage

Tonix Pharmaceuticals Announces Major Medicare Coverage Agreement for TONMYA, Expanding U.S. Access to Approximately 145 Million Covered Lives

Tonix Pharmaceuticals announced a major managed Medicare agreement for TONMYA, adding approximately 9 million Medicare lives starting January 1, 2027, and bringing total covered lives to 145 million. The company is also expanding its sales force by 50 representatives to enhance a

Tone
Positive 73/100
Event
Market update
Published
14 Jul 2026 11:13
Source
Quiver Quantitative
GlobeNewswire Direct company coverage

Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®

Tonix Pharmaceuticals announced a new agreement for TONMYA (cyclobenzaprine HCl sublingual tablets) with a major managed Medicare payer, effective January 1, 2027, adding approximately 9 million Medicare lives. This expands TONMYA's coverage to about 46% of all covered lives in t

Tone
Positive 73/100
Event
Market update
Published
13 Jul 2026 11:40
Source
GlobeNewswire
TradingView Direct company coverage

Tonix Pharmaceuticals Adds Medicare Part D Coverage for TONMYA, Expands Sales Force

Tonix Pharmaceuticals announced a PBM agreement to secure Medicare Part D coverage for TONMYA, effective January 1, 2027, significantly expanding patient access to approximately 9 million beneficiaries. This new coverage, combined with existing Medicaid and commercial agreements,

Tone
Positive 90/100
Event
Market update
Published
13 Jul 2026 11:11
Source
TradingView
Stock Titan Direct company coverage

Tonix Pharmaceuticals (NASDAQ: TNXP) secures PBM Medicare pact, targeting 145M TONMYA covered lives

Tonix Pharmaceuticals has secured an agreement with a pharmacy benefit manager for TONMYA coverage for Medicare Part D beneficiaries, effective January 1, 2027, adding approximately 9 million Medicare lives. This new agreement, combined with existing commercial and Medicaid cover

Tone
Positive 71/100
Event
Market update
Published
13 Jul 2026 11:11
Source
Stock Titan
Stock Titan Direct company coverage

Fibromyalgia drug TONMYA to reach 145M covered lives by 2027

Tonix Pharmaceuticals announced a major managed Medicare agreement for its fibromyalgia drug, TONMYA, adding approximately 9 million Medicare lives, bringing the total projected pharmacy coverage to 145 million covered lives by January 1, 2027. This expansion, combined with exist

Tone
Positive 74/100
Event
Market update
Published
13 Jul 2026 10:59
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 Tonix Pharmaceuticals Holding Corp For: 9 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Tonix Pharmaceuticals Holding Corp. on July 9, 2026. The brief entry provides the company's stock symbol (TNXP) and notes a 1.96% increase, indicating recent activity in the company's stock.

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 14:41
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Tonix (NASDAQ: TNXP) CFO adds 1,453 shares through 2025 employee stock plan

Tonix Pharmaceuticals Holding Corp.'s CFO, Bradley Saenger, acquired 1,453 shares of common stock at $10.914 per share through the company's 2025 Employee Stock Purchase Plan. This transaction, coded as "J" for "other acquisition or disposition," is compensation-related and not a

Tone
Neutral 50/100
Event
Deals and strategy
Published
09 Jul 2026 12:51
Source
Stock Titan
Stock Traders Daily Direct company coverage

Technical Reactions to TNXP Trends in Macro Strategies

The article provides a technical analysis of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) with insights into near, mid-term, and long-term trends. It highlights a strong sentiment in the near and mid-term, but a weak long-term outlook, identifying an exceptional risk-reward

Tone
Negative 38/100
Event
Guidance
Published
02 Jul 2026 23:30
Source
Stock Traders Daily
GlobeNewswire Direct company coverage

Tonix Pharmaceuticals Announces First Patient Enrolled in

Tonix Pharmaceuticals announced the enrollment of the first patient in its Phase 2 HORIZON study for TNX-102 SL, a treatment for Major Depressive Disorder (MDD). The study evaluates TNX-102 SL 5.6 mg as a first-line monotherapy, targeting disturbed sleep quality in MDD patients.

Tone
Positive 70/100
Event
Market update
Published
29 Jun 2026 20:40
Source
GlobeNewswire
Bitget Direct company coverage

Tonix Pharmaceuticals Holding Corp. has enrolled the first patient in its Phase 2 “HORIZON” study of TNX-102 SL (sublingual tablet) for the treatment of major depressive disorder (MDD).

Tonix Pharmaceuticals Holding Corp. has enrolled the first patient in its Phase 2 "HORIZON" study for TNX-102 SL, a sublingual tablet designed to treat major depressive disorder (MDD). This milestone, reported to the SEC, marks significant progress in the clinical development of

Tone
Positive 74/100
Event
Market update
Published
29 Jun 2026 20:11
Source
Bitget
Stock Titan Direct company coverage

Tonix Pharmaceuticals (TNXP) enrolls first patient in Phase 2 HORIZON MDD trial

Tonix Pharmaceuticals has announced the enrollment of the first patient in its Phase 2 HORIZON trial for TNX-102 SL 5.6 mg as a first-line monotherapy for adults with major depressive disorder (MDD). This 6-week, randomized, double-blind, placebo-controlled study plans to enroll

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 20:10
Source
Stock Titan
grafa.com Direct company coverage

Tonix enrolls first patient in Phase 2 depression study

Tonix Pharmaceuticals has enrolled the first patient in its Phase 2 HORIZON study for major depressive disorder. The trial will involve approximately 360 patients across 30 U.S. sites and will assess TNX-102 SL (TONMYA), which is already FDA-approved for fibromyalgia, as a first-

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 16:03
Source
grafa.com
Quiver Quantitative Direct company coverage

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for Major Depressive Disorder

Tonix Pharmaceuticals has announced the enrollment of the first patient in its Phase 2 HORIZON study for TNX-102 SL, investigating its use as a first-line treatment for major depressive disorder (MDD). The study aims to enroll approximately 360 participants to evaluate changes in

Tone
Positive 66/100
Event
Market update
Published
29 Jun 2026 11:30
Source
Quiver Quantitative
Stock Titan Direct company coverage

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

Tonix Pharmaceuticals has enrolled the first patient in its Phase 2 HORIZON study for TNX-102 SL in treating major depressive disorder (MDD). The 6-week, randomized, double-blind, placebo-controlled trial aims to enroll approximately 360 adults and will evaluate the drug as a fir

Tone
Positive 67/100
Event
Market update
Published
29 Jun 2026 11:11
Source
Stock Titan